Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

NCT02450539 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02450539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02450539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
August 6, 2015
Completion date
July 29, 2020
Enrollment
159 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer stage iv